Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Short-term Investments (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Short-term Investments data on record, last reported at $401.6 million in Q3 2023.

  • For Q3 2023, Short-term Investments rose 20.49% year-over-year to $401.6 million; the TTM value through Sep 2023 reached $401.6 million, up 20.49%, while the annual FY2022 figure was $311.1 million, 34.87% up from the prior year.
  • Short-term Investments reached $401.6 million in Q3 2023 per CGEM's latest filing, up from $350.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $401.6 million in Q3 2023 and bottomed at $42.0 million in Q4 2020.
  • Average Short-term Investments over 4 years is $252.2 million, with a median of $248.1 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: surged 449.16% in 2021, then increased 12.5% in 2023.
  • A 4-year view of Short-term Investments shows it stood at $42.0 million in 2020, then soared by 449.16% to $230.7 million in 2021, then skyrocketed by 34.87% to $311.1 million in 2022, then rose by 29.07% to $401.6 million in 2023.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $401.6 million in Q3 2023, $350.0 million in Q2 2023, and $268.6 million in Q1 2023.